Tradegate
28.08.26 | 14:07
3,264 Euro
+2,51 % +0,080
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,164 | 3,244 | 28.08. | |
| 3,168 | 3,200 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026 | 3 | GlobeNewswire (USA) | ||
| 08.07. | OSE Immunotherapeutics: Half-Year Report on Liquidity Contract with Invest Securities | 4 | GlobeNewswire (USA) | ||
| 03.06. | OSE Immunotherapeutics: Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting | 6 | GlobeNewswire (USA) | ||
| 03.06. | OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document | 198 | GlobeNewswire (Europe) | 2025 Audited financial statements are consistent with Unaudited financial statements previously reported on April 30, 2026The IRIS Financing announced on May 28, 2026, was added as a subsequent eventConfirmed... ► Artikel lesen | |
| OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing | 325 | GlobeNewswire (Europe) | First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in EuropeGross proceeds could amount to €19.3 million based on... ► Artikel lesen | |
| 22.05. | OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi in Recurrent Ovarian Cancer | 283 | GlobeNewswire (Europe) | OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026... ► Artikel lesen | |
| 30.04. | OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position | 435 | GlobeNewswire (Europe) | OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1€22.7 and €17.0 million cash position as of December 31, 2025, and... ► Artikel lesen | |
| 27.04. | OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients | 379 | GlobeNewswire (Europe) | Nantes, France, April 27, 2026 - 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S.... ► Artikel lesen | |
| 23.04. | OSE Immunotherapeutics' ovarian cancer trial to be presented at ASCO | 2 | Investing.com | ||
| 23.04. | OSE Immunotherapeutics stellt Studiendaten zu Eierstockkrebs auf ASCO-Jahrestagung vor | 1 | Investing.com Deutsch | ||
| 23.04. | OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi in Ovarian Cancer at the ASCO 2026 Meeting | 2 | GlobeNewswire (USA) | ||
| 15.04. | OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting | 3 | GlobeNewswire (USA) | ||
| 14.04. | OSE Immunotherapeutics Evolves its Leadership Team | 411 | GlobeNewswire (Europe) | OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 - 6:00pm CEST - OSE Immunotherapeutics... ► Artikel lesen | |
| 16.03. | OSE Immunotherapeutics Announces its 2026 Financial Calendar | 4 | GlobeNewswire (USA) | ||
| 10.03. | OSE Immunotherapeutics Names Marc Le Bozec Permanent CEO; Stock Up 4% | 1 | RTTNews | ||
| 10.03. | OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth | 216 | GlobeNewswire (Europe) | Nantes, France, March 10, 2026 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive... ► Artikel lesen | |
| 03.03. | OSE Immunotherapeutics - Reaffirmed dedication to core assets | 613 | Edison Investment Research | OSE Immunotherapeutics has reaffirmed its strategy of streamlining its clinical pipeline following some developments to its partnered assets. For ABBV-230 (OSE-230), partnered with AbbVie, OSE had previously... ► Artikel lesen | |
| 02.03. | OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi | 422 | GlobeNewswire (Europe) | Streamlining of selected non-strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no... ► Artikel lesen | |
| 26.02. | OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi in Non-Small Cell Lung Cancer | 650 | GlobeNewswire (Europe) | NANTES, France, February 26, 2026 - 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent Data Monitoring Committee (IDMC) has issued a second... ► Artikel lesen | |
| 29.01. | OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab | 274 | GlobeNewswire (Europe) | OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationaleChronic Pouchitis offers... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| EVOTEC | 3,348 | -1,06 % | Rheinmetall-Aktie verkaufen? Evotec mit KI-Fantasie? Lahontan Gold hebt Ressourcenschätzung um 22 %! | Soll man die Rheinmetall-Aktie verkaufen? Dazu rät jedenfalls mwb Research. Die Analysten sehen Rheinmetall operativ weiterhin als klaren Gewinner des europäischen Rüstungsbooms. Doch die Erwartungen... ► Artikel lesen | |
| BB BIOTECH | 59,40 | -0,17 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| MODERNA | 119,06 | -0,03 % | Moderna Aktie: Was für ein Wahnsinn bei Moderna! Kippt aber jetzt die Stimmung?! | © Foto: Finanznachrichten (Symbolbild wurde mit KI erstellt)Erst ein Kurssprung wie ihn kaum eine Aktie je erlebt hat, dann der schnelle Absturz, aber kommt jetzt wieder eine Erholung? Moderna sorgt... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,610 | +1,16 % | EQS-News: Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in China | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Studie
Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy |
Das Unternehmen OSE IMMUNOTHERAPEUTICS SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,264 Euro und damit +2,51 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSE IMMUNOTHERAPEUTICS SA finden Sie auf Wallstreet Online.